🇺🇸 FDA

Intelligence · Clinical Pipeline

Vertex Pharmaceuticals (Australia) Pipeline

All ClinicalTrials.gov programs at Vertex Pharmaceuticals (Australia) — phase, modality, and trial IDs.

Programs
159

Quick answer

Vertex Pharmaceuticals (Australia) has 159 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. VX-880

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetes Mellitus, Type 1

    phase 3 mab active

    1 trial

  2. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  3. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  4. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  5. Cethrin

    Vertex Pharmaceuticals (Australia) Pty.

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial

  6. Inaxaplin

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 2 small molecule active

    1 trial

  7. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  8. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  9. Ivacaftor 25 mg/75 mg

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  10. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  11. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  12. P-1037

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  13. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 2 small molecule active

    1 trial

  14. PREGABALIN, VX-993 tablet, VX-993 Placebo, VX-993 tablet, PREGABALIN, Pregabalin placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  15. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  16. Placebo (matched to VX-121 suspension)

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  17. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  18. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  19. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  20. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  21. Telaprevir and Sofosbuvir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  22. Tezacaftor/Ivacaftor + Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  23. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial

  24. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  25. VCH-759 (BCH-27759)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  26. VX-121

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  27. VX-135

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    3 trials

  28. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Glomerulosclerosis, Focal Segmental

    phase 2 small molecule completed

    1 trial

  29. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  30. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  31. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Small Fiber Neuropathy

    phase 2 small molecule completed

    1 trial

  32. VX-152

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  33. VX-222

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    2 trials

  34. VX-264

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  35. VX-264 Implant

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  36. VX-371

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Ciliary Dyskinesia

    phase 2 small molecule completed

    1 trial

  37. VX-371 + HS

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  38. VX-407

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    4 trials

  39. VX-407 tablet

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    1 trial

  40. VX-522 mRNA therapy

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  41. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Painful Lumbosacral Radiculopathy

    phase 2 small molecule completed

    1 trial

  42. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  43. VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule terminated

    2 trials

  44. VX-659

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  45. VX-661

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  46. VX-670

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    2 trials

  47. VX-670 Solution for Injection/Infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  48. VX-670 Solution for Injection/Infusion, 0.9% saline solution (w/v)

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Vertex Pharmaceuticals (Australia) have?

159 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.